改善非恶性血液病治疗效果的优先事项：来自血液与骨髓移植临床试验网络的报告。
Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.
作者信息
Levine John E, Antin Joseph H, Allen Carl E, Burroughs Lauri M, Cooke Kenneth R, Devine Steven, Heslop Helen, Nakamura Ryotaro, Talano Julie An, Yanik Gregory, DiFronzo Nancy
机构信息
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
出版信息
Biol Blood Marrow Transplant. 2020 May;26(5):e94-e100. doi: 10.1016/j.bbmt.2020.01.024. Epub 2020 Feb 5.
Abstract
Nonmalignant blood diseases such as bone marrow failure disorders, immune dysregulation disorders, and hemoglobinopathies often lead to shortened life spans and poor quality of life. Many of these diseases can be cured with allogeneic hematopoietic cell transplantation, but patients are often not offered the procedure because of perceived insufficient efficacy and/or excess toxicity. In 2018, the Blood and Marrow Transplant Clinical Trials Network convened a task force to identify the most urgently needed yet feasible clinical trials with potential to improve the outcomes for patients with nonmalignant diseases. This report summarizes the task force discussions and specifies the network plans for clinical trial development for nonmalignant blood diseases.
摘要
非恶性血液疾病，如骨髓衰竭症、免疫调节紊乱症和血红蛋白病，常常导致寿命缩短和生活质量低下。这些疾病中的许多都可以通过异基因造血细胞移植治愈，但由于认为疗效不足和/或毒性过大，患者往往无法接受该治疗程序。2018年，血液和骨髓移植临床试验网络召集了一个特别工作组，以确定最迫切需要且可行的临床试验，这些试验有可能改善非恶性疾病患者的治疗结果。本报告总结了特别工作组的讨论情况，并明确了非恶性血液疾病临床试验开发的网络计划。
相似文献
1
Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.改善非恶性血液病治疗效果的优先事项：来自血液与骨髓移植临床试验网络的报告。
Biol Blood Marrow Transplant. 2020 May;26(5):e94-e100. doi: 10.1016/j.bbmt.2020.01.024. Epub 2020 Feb 5.
2
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.非清髓性干细胞移植和细胞疗法作为传统骨髓移植（伴有致死性细胞消减）的替代方法，用于治疗恶性和非恶性血液系统疾病。
Blood. 1998 Feb 1;91(3):756-63.
3
The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies.第二届儿科血液与骨髓移植协会国际儿童造血细胞移植后迟发效应共识会议：界定因免疫缺陷、遗传性骨髓衰竭疾病和血红蛋白病接受造血细胞移植儿童的独特迟发效应。
Biol Blood Marrow Transplant. 2017 Jan;23(1):24-29. doi: 10.1016/j.bbmt.2016.10.004. Epub 2016 Oct 11.
4
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.采用仅含化疗的减瘤方案以及来自人类白细胞抗原匹配或不匹配供者的T细胞去除移植物，对非恶性血液系统疾病进行异基因造血干细胞移植。
Pediatr Hematol Oncol. 2016 Sep;33(6):347-358. doi: 10.1080/08880018.2016.1204399. Epub 2016 Oct 7.
5
Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.采用移植后环磷酰胺的替代供体造血干细胞移植治疗非恶性疾病。
Biol Blood Marrow Transplant. 2016 May;22(5):895-901. doi: 10.1016/j.bbmt.2016.02.001. Epub 2016 Feb 6.
6
Bone marrow transplantation for nonmalignant diseases.非恶性疾病的骨髓移植
J Hematother Stem Cell Res. 2002 Apr;11(2):377-87. doi: 10.1089/152581602753658565.
7
Basics of Hematopoietic Cell Transplantation for Primary Care Physicians and Internists.基层医疗医生和内科医生的造血细胞移植基础
Prim Care. 2016 Dec;43(4):693-701. doi: 10.1016/j.pop.2016.07.003.
8
Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.非恶性疾病无关供者及替代供者造血细胞移植的进展
Curr Opin Pediatr. 2015 Feb;27(1):9-17. doi: 10.1097/MOP.0000000000000179.
9
Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.“微移植”综述：非清髓性异基因造血干细胞移植
Int J Hematol. 2003 Jan;77(1):3-14. doi: 10.1007/BF02982597.
10
Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).2011 - 2012年东地中海区域造血干细胞移植：代表东地中海血液与骨髓移植组（EMBMT）的综合报告。
Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):167-75. doi: 10.1016/j.hemonc.2015.09.002. Epub 2015 Oct 1.
引用本文的文献
1
Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter.经外周静脉穿刺中心静脉置管进行冷冻保存干细胞输注的安全性
Cancers (Basel). 2023 Feb 20;15(4):1338. doi: 10.3390/cancers15041338.
2
CXCR6 and NKG2C Natural Killer Cells Are Distinct With Unique Phenotypic and Functional Attributes Following Bone Marrow Transplantation.骨髓移植后，CXCR6 和 NKG2C 自然杀伤细胞具有独特的表型和功能特征。
Front Immunol. 2022 Jun 29;13:886835. doi: 10.3389/fimmu.2022.886835. eCollection 2022.
3
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.血液和骨髓移植临床研究网络 2021 年科学研讨会：展望未来，网络迎来成立 20 周年。
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
本文引用的文献
1
Alpha-1 Antitrypsin Attenuates Acute Lung Allograft Injury in a Rat Lung Transplant Model.α-1抗胰蛋白酶减轻大鼠肺移植模型中的急性肺移植损伤。
Transplant Direct. 2019 May 29;5(6):e458. doi: 10.1097/TXD.0000000000000898. eCollection 2019 Jun.
2
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.成人噬血细胞性淋巴组织细胞增生症的治疗建议。
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
3
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.经输血依赖型β-地中海贫血影响的成年和儿科患者的骨内造血干细胞基因治疗。
Nat Med. 2019 Feb;25(2):234-241. doi: 10.1038/s41591-018-0301-6. Epub 2019 Jan 21.
4
Emapalumab: First Global Approval.依马芦单抗：全球首次获批。
Drugs. 2019 Jan;79(1):99-103. doi: 10.1007/s40265-018-1046-8.
5
The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease.γ干扰素在造血干细胞发育、稳态及疾病中的作用
Curr Stem Cell Rep. 2018;4(3):264-271. doi: 10.1007/s40778-018-0139-3. Epub 2018 Jul 23.
6
Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.造血干细胞移植存活者的心血管疾病预测。
Blood Adv. 2018 Jul 24;2(14):1756-1764. doi: 10.1182/bloodadvances.2018019117.
7
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.HLH 和原发性免疫缺陷病的造血细胞移植的低强度预处理。
Blood. 2018 Sep 27;132(13):1438-1451. doi: 10.1182/blood-2018-01-828277. Epub 2018 Jul 11.
8
Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.三氧化二砷、氟达拉滨和低剂量全身照射联合异基因造血细胞移植治疗儿童和青年急性髓系白血病或骨髓增生异常综合征：儿科血液和骨髓移植联盟的前瞻性 II 期试验。
Biol Blood Marrow Transplant. 2018 Aug;24(8):1651-1656. doi: 10.1016/j.bbmt.2018.04.025. Epub 2018 May 9.
9
Population Screening for Hemoglobinopathies.人群血红蛋白病筛查。
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:355-380. doi: 10.1146/annurev-genom-091416-035451. Epub 2018 May 11.
10
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.输血依赖型β-地中海贫血症患者的基因治疗。
N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.
Zotero 插件